Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 7,000 Shares

Key Points

• Insider Joseph Lyssikatos sold 7,000 shares of Enliven Therapeutics at an average price of $19.39, totaling $135,730, which resulted in a 0.74% decrease in their ownership.
• Enliven Therapeutics reported a quarterly EPS of ($0.49), surpassing analysts' estimates of ($0.53), amidst expectations of a projected ($1.95) EPS for the current year.
• The stock currently has a consensus rating of "Buy" and a target price of $41.20, with several analysts indicating higher price targets.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 7,000 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $19.39, for a total value of $135,730.00. Following the completion of the transaction, the insider directly owned 933,188 shares in the company, valued at approximately $18,094,515.32. This represents a 0.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock traded down $0.73 during midday trading on Tuesday, reaching $19.19. The company had a trading volume of 433,561 shares, compared to its average volume of 399,818. The stock has a fifty day moving average price of $20.05 and a 200 day moving average price of $19.64. The firm has a market cap of $1.14 billion, a PE ratio of -9.60 and a beta of 0.88. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. As a group, sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on ELVN shares. HC Wainwright boosted their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. The Goldman Sachs Group started coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They set a "buy" rating and a $37.00 target price on the stock. Finally, Robert W. Baird raised their price target on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, Enliven Therapeutics has a consensus rating of "Buy" and a consensus target price of $41.20.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC lifted its position in Enliven Therapeutics by 3,058.1% in the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock valued at $53,000 after acquiring an additional 2,630 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Enliven Therapeutics in the first quarter valued at approximately $60,000. BNP Paribas Financial Markets boosted its position in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after buying an additional 930 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock worth $106,000 after buying an additional 3,490 shares in the last quarter. Finally, KLP Kapitalforvaltning AS grew its holdings in Enliven Therapeutics by 58.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company's stock worth $136,000 after buying an additional 2,500 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.